In response to the FDA’s shortage decision, Hims & Hers is launching a new GLP-1 tracker, allowing patients to self-identify, provide ...

Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com launched a rival service that offers upfront pricing ...

Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.'s latest push into healthcare will disrupt Hims & Hers' business.

"Full House" actor Dave Coulier, 65, revealed he has stage 3 non-Hodgkin's lymphoma. ( People) The latest tally of the ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

Shares of Hims & Hers ($HIMS) plummeted nearly 15% on Thursday after Amazon.com, Inc. ($AMZN) launched its new Amazon One ...

(Irwin, 11/13) Yahoo Finance: Hims & Hers Launches GLP-1 Tracker In Response To FDA's Shortage Decision Hims & Hers is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s ...

The tech company’s prices appear set to undercut the long list of competing telehealth companies that rely on aggressive ...

Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.

BofA lowered its rating of Hims & Hers (HIMS) to underperform from buy, citing Amazon’s (AMZN) push into the hair loss and ...

Hims & Hers (HIMS) is down -17.7%, or -$4.88 to $22.72. Published first on TheFly – the ultimate source for real-time, ...